Postherpetic Neuralgia: Current Evidence on the Topical Film-Forming Spray with Bupivacaine Hydrochloride and a Review of Available Treatment Strategies

• Published in: Advances in therapy Vol. 37; no. 5; pp. 2003 - 2016
• Main Authors: Ngo, Anh L., Urits, Ivan, Yilmaz, Melis, Fortier, Luc, Anya, Anthony, Oh, Jae Hak, Berger, Amnon A., Kassem, Hisham, Sanchez, Manuel G., Kaye, Alan D., Urman, Richard D., Herron, Edwin W., Cornett, Elyse M., Viswanath, Omar
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.05.2020
• Subjects: Analgesics - economics; Analgesics - therapeutic use; Analgesics, Opioid - therapeutic use; Bupivacaine - economics; Bupivacaine - therapeutic use; Cardiology; Chronic Pain - drug therapy; Endocrinology; Health Care Costs; Herpes Zoster - complications; Herpes Zoster - drug therapy; Humans; Internal Medicine; Medicine; Medicine & Public Health; Neuralgia, Postherpetic - drug therapy; Neuralgia, Postherpetic - economics; Neuralgia, Postherpetic - etiology; Oncology; Pharmacology/Toxicology; Review; Rheumatology; Herpes zoster; Bupivacaine; VZV; Shingles; Post-herpetic neuralgia; Lidocaine; Film-forming systems; Local anesthetics
• ISSN: 0741-238X; 1865-8652
• DOI: 10.1007/s12325-020-01335-9

Purpose of Review This is a comprehensive review of the literature about the use of bupivacaine hydrochloride for the treatment of post-herpetic neuralgia (PHN). It briefly reviews the background, biology, diagnosis and conventional treatment for PHN, and then introduces and compares the recent evidence for the use of topical bupivacaine. Recent Findings PHN is defined by pain lasting 90 days or more after the initial presentation of herpes zoster (“Shingles”, HZ) rash and is the most common complication of this disease. A product of re-activation of the Varicella-Zoster virus (VZV), HZ is diagnosed more than 1 million times annually in the United States. Approximately 20% of patients with HZ will experience PHN and will continue to suffer intermittent neuropathic symptoms, including itching and pain, that is sharp, stabbing, throbbing or burning, with the pain localized to the site of their original rash. This long-lasting pain compares with the severity of long-standing rheumatics and osteo-arthritis and is accompanied by severe allodynia causing significant suffering, and a financial burden that is manifested in both healthcare costs and loss of quality-adjusted life years. Prevention of PHN may be achieved with the Zoster vaccine, although there is still a large segment of unvaccinated population. Moreover, the Zoster vaccine is not always effective for prevention. Current treatment includes medical (systemic tricyclic antidepressants, anticonvulsants and opioids, topical lidocaine and capsaicin) and interventional (subcutaneous Botox injections, nerve blocks and nerve stimulation) therapies. These therapies are not always effective, and each carries their own profile of side effects and risks. Moreover, up to 50% of patients with PHN are refractory to management. Recent evidence is emerging to support the use of topical local anesthetics for the treatment of PHN. Two small studies recently found topical lidocaine spray to be effective in treating paroxysmal pain attacks associated with PHN. Bupivacaine is a longer-lasting local anesthetic, and a film-forming formulation allows easy and durable application to the affected skin. Recent studies show that topical film-forming bupivacaine is safe and as effective as lidocaine for the treatment of PHN. Summary PHN is an important though common complication of HZ and can cause long-lasting pain and disability. Current treatment for PNH is limited by efficacy and safety profiles of individual therapies. Recent evidence points to topical local anesthetics as an effective and safe alternative to conventional therapy. Film-forming bupivacaine may offer a durable and safe option for this otherwise difficult to treat syndrome.